GlassScriptPhysician profile
Matthew D Mcelveen
NPI 1245395573
$2,756.01
in general payments reported to CMS, 2019-2025
48 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $232 · 2021: $415 · 2022: $367 · 2023: $189 · 2024: $483 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308 · Education: $81.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.72 |
| Education | $81.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $251.74 | 2019-2025 | Opdivo |
| Celgene Corporation | $190.41 | 2019-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $179.55 | 2019-2025 | Keytruda, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $156.29 | 2019-2025 | Enhertu, Imfinzi |
| Pfizer INC. | $129.51 | 2019-2025 | |
| Epizyme, INC. | $125.00 | 2020 | |
| Janssen Biotech, INC. | $123.40 | 2020-2025 | Tecvayli, Darzalex, Rybrevant |
| Gilead Sciences, INC. | $109.38 | 2021-2024 | Trodelvy |
| Abbvie INC. | $104.80 | 2024-2025 | |
| Daiichi Sankyo INC. | $100.72 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $100.33 | 2022-2025 | Vyloy, Cresemba, Xtandi |
| Genentech USA, INC. | $96.28 | 2022-2024 | Polivy, Tecentriq Hybreza, Itovebi |
| Beigene USA, INC. | $95.25 | 2020-2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $86.09 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $81.00 | 2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcelveen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.